sinedol 500 i.j./1 g+ 150 mg/1 g+ 25 mg/1 g gel
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - dekspantenol, dimetilsulfoksid, heparin - gel - 500 i.j./1 g+ 150 mg/1 g+ 25 mg/1 g - 1 g gela sadrži: 500 i.j. heparinnatrijuma 150 mg dimetilsulfoksida 25 mg dekspantenola
sinedol 500 i.j./1 g+ 150 mg/1 g+ 25 mg/1 g gel
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - dekspantenol, dimetilsulfoksid, heparin - gel - 500 i.j./1 g+ 150 mg/1 g+ 25 mg/1 g - 1 g gela sadrži: 500 i.j. heparinnatrijuma 150 mg dimetilsulfoksida 25 mg dekspantenola
otiprin®
siki-vet d.o.o., zagreb, hrvatska - kloramfenikol, deksametazon, benzilbenzoat i dimetilsulfoksid - otopina, kapi za uho - pasa
prurivet
siki-vet d.o.o., zagreb, hrvatska - kloramfenikol, benzilbenzoat, deksametazon i dimetilsulfoksid - otopina za primjenu na koži - pasa
verrucutan 5 mg/g + 100 mg/g otopina za kožu
mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - fluorouracil salicilatna kiselina - otopina za kožu - 5 mg/g + 100 mg/g - urbroj: 1 g otopine sadrži 5 mg fluorouracila i 100 mg salicilatne kiseline
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - ostali lijekovi protiv živčanog sustava - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.